Ananda Pharma publishes annual report, advances CBD drug trials

LONDON - Ananda Pharma plc (AQSE:ANA, OTCQB: ANANF) has published its annual report and accounts for the year ended January 31, 2025, revealing progress in its cannabidiol (CBD) medicine development program.

The UK-based biopharmaceutical company reported an operating loss of £3.77 million for the fiscal year, significantly reduced from the £6.93 million loss recorded in the previous year. The company nearly tripled its research and development expenditure to £298,814, up from £123,000 in 2024.

In September 2024, Ananda raised approximately £2.15 million plus a broker option placing of £79,966 to finance its drug development initiatives, including the manufacture of its MRX1 drug candidate for clinical trials.

The company has advanced the manufacturing of its proprietary MRX1 CBD formulation and produced one batch as an Investigational Medicinal Product for use in its sponsored Phase 1 trial and partner-sponsored Phase 2 clinical trials. The Phase 1 trial commenced in July 2025 in Australia.

Ananda is currently providing its formulations for several clinical studies, including a Phase 2a feasibility trial for endometriosis-related pain at the University of Edinburgh, a Phase 2 efficacy study for chemotherapy-induced peripheral neuropathy, and two Phase 3 clinical trials for refractory epilepsies in partnership with University College London and Great Ormond Street Hospital.

Following the end of the reporting period, Ananda appointed three key advisors, including Chris Tovey, former COO of GW Pharmaceuticals (OTC:GWPRF), and Giles Moss, former GM Europe for GW Pharmaceuticals. The company also commenced trading on the US-based OTCQB exchange.

Chairman Charles Morgan stated that the company’s focus for the year ahead will be developing its US market approach, as "the United States of America is the single largest, most important and most influential market for pharmaceuticals."

The information in this article is based on a press release statement from Ananda Pharma.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.